<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Case report: Late-onset BK polyomavirus-associated nephropathy in kidney transplant recipients</dc:title><dc:creator>Belčič Mikič,	Tanja	(Avtor)
	</dc:creator><dc:creator>Bošnjak,	Matic	(Avtor)
	</dc:creator><dc:creator>Arnol,	Miha	(Avtor)
	</dc:creator><dc:subject>BK polyomavirus-associated nephropathy</dc:subject><dc:subject>diagnosis</dc:subject><dc:subject>immunosuppression</dc:subject><dc:subject>kidney transplantation</dc:subject><dc:subject>pathophysiology</dc:subject><dc:description>BK polyomavirus–associated nephropathy (BKPyVAN) results from primary infection or reactivation of BK polyomavirus (BKPyV) and remains a significant complication in kidney transplant recipients, contributing to allograft dysfunction and premature allograft loss. Most cases occur within the first 2 years post-transplant, when cell-mediated immunity is most suppressed due to induction immunosuppression. Here, we describe two unusual cases of late-onset BKPyVAN occurring in the absence of intensified immunosuppression and provide a review of potential mechanisms underlying its development in kidney transplant recipients. In the first patient, BKPyVAN developed 9 years after transplantation during maintenance dual immunosuppression with tacrolimus and mycophenolic acid, without prior rejection episodes or exposure to intensified immunosuppression. In the second patient, BKPyVAN first occurred 3 years post-transplant in the setting of concomitant cytomegalovirus colitis, also during dual immunosuppression with tacrolimus and mycophenolic acid. Despite reduction of immunosuppression, BKPyVAN persisted at 1-year follow-up and was associated with a gradual decline in allograft function. These cases highlight that late-onset BKPyVAN may develop even without intensified immunosuppression and can lead to significant allograft injury. Improved strategies are needed to identify patients at risk for late-onset BKPyVAN and to optimize therapeutic management.</dc:description><dc:date>2026</dc:date><dc:date>2026-07-07 10:47:32</dc:date><dc:type>Neznano</dc:type><dc:identifier>30848</dc:identifier><dc:identifier>UDK: 616.61</dc:identifier><dc:identifier>ISSN pri članku: 2296-858X</dc:identifier><dc:identifier>DOI: 10.3389/fmed.2026.1799421</dc:identifier><dc:identifier>COBISS_ID: 283840515</dc:identifier><dc:language>sl</dc:language></metadata>
